Ventyx Biosciences' Phase 2 trial of TYK2 inhibitor VTX958 for Crohn's disease failed to meet primary endpoint; shares fell 24.4%.

Ventyx Biosciences' Phase 2 trial of allosteric TYK2 inhibitor VTX958 for Crohn's disease failed to meet primary endpoint; shares fell 24.4%. The drug showed nominal statistical significance on secondary endpoint of endoscopic response, but the high placebo response led to primary endpoint failure. Ventyx does not plan to conduct further trials of VTX958 with internal resources.